10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
PFIZER INC | |||
Ticker: PFE Fiscal Year: 2022 | |||
Consolidated Statements of Income | |||
Period Ending Dec 31, 2022 10-K (Filed: Feb 23, 2023) | |||
| (In Millions) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
| Revenues | $ 100,330 | 81,288 | 41,651 |
| Costs and expenses: | |||
| Cost of sales | 34,344 | 30,821 | 8,484 |
| Selling, informational and administrative expenses | 13,677 | 12,703 | 11,597 [1] |
| Research and development expenses | 11,428 | 10,360 | 8,709 |
| Acquired in-process research and development expenses | 953 [2] | 3,469 | 684 |
| Amortization of intangible assets | 3,609 | 3,700 | 3,348 |
| Restructuring charges and certain acquisition-related costs | 1,375 | 802 | 579 |
| Other (income)/deductionsnet | 217 | (4,878) | 1,213 |
| Income from continuing operations before provision/(benefit) for taxes on income | 34,729 | 24,311 | 7,036 |
| Provision/(benefit) for taxes on income | 3,328 | 1,852 | 370 |
| Income from continuing operations | 31,401 | 22,459 | 6,666 |
| Discontinued operationsnet of tax | 6 | (434) | 2,529 |
| Net income before allocation to noncontrolling interests | 31,407 | 22,025 | 9,195 |
| Less: Net income attributable to noncontrolling interests | 35 | 45 | 36 |
| Net income attributable to Pfizer Inc. common shareholders | 31,372 | 21,979 | 9,159 |
| Earnings per common sharebasic: | |||
| Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) | 5.59 | 4.00 | 1.19 |
| Discontinued operationsnet of tax (in dollars per share) | 0.00 | (0.08) | 0.46 |
| Net income attributable to Pfizer Inc. common shareholders (in dollars per share) | 5.59 | 3.92 | 1.65 |
| Earnings per common sharediluted: | |||
| Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) | 5.47 | 3.93 | 1.18 |
| Discontinued operationsnet of tax (in dollars per share) | 0.00 | (0.08) | 0.45 |
| Net income attributable to Pfizer Inc. common shareholders (in dollars per share) | 5.47 | 3.85 | 1.63 |
| Weighted-average sharesbasic | 5,608 | 5,601 | 5,555 |
| Weighted-average sharesdiluted | 5,733 | 5,708 | 5,632 |
| [1] Exclusive of amortization of intangible assets. | |||
| [2] See Note 1L. | |||
| External Links | |
| PFIZER INC (PFE) Fiscal Year 2022 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |